Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR ESMO Clinical Practice Guideline Express Update on the management of epithelial... January 28, 2026 Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with... December 18, 2023 ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 How to Plan a ‘Safecation’ August 17, 2020 Load more HOT NEWS Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute... EMA Recommends Granting a Marketing Authorisation for Catumaxomab
